Prostate Cancer Research - Symptoms, Genetics, Screening, Treatment, Information

Prostate Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Prostate Cancer, including details on symptoms, genetics, screening, treatment, information.


Prostate Cancer Research Today

Home

View Latest Issue

Information About Prostate Cancer

Books on Prostate Cancer

Advertising in Research Today

View Other Research Today Publications



Volume 8 (2011), Issue 2 (February)

  1. Characterizing interfraction variations and their dosimetric effects in prostate cancer radiotherapy.
    Int J Radiat Oncol Biol Phys, 79(3): 909-14. [Abstract] [Full-text]
  2. Volumetric arc therapy and intensity-modulated radiotherapy for primary prostate radiotherapy with simultaneous integrated boost to intraprostatic lesion with 6 and 18 MV: a planning comparison study.
    Int J Radiat Oncol Biol Phys, 79(3): 920-6. [Abstract] [Full-text]
  3. Vector analysis of prostate patient setup with image-guided radiation therapy via kV cone beam computed tomography.
    Int J Radiat Oncol Biol Phys, 79(3): 915-9. [Abstract] [Full-text]
  4. Overall survival benefit from postoperative radiation therapy for organ-confined, margin-positive prostate cancer.
    Int J Radiat Oncol Biol Phys, 79(3): 719-23. [Abstract] [Full-text]
  5. Predictors of androgen deprivation therapy efficacy combined with prostatic irradiation: the central role of tumor stage and radiation dose.
    Int J Radiat Oncol Biol Phys, 79(3): 724-31. [Abstract] [Full-text]
  6. Secondary malignancies from prostate cancer radiation treatment: a risk analysis of the influence of target margins and fractionation patterns.
    Int J Radiat Oncol Biol Phys, 79(3): 738-46. [Abstract] [Full-text]
  7. Improved biochemical outcomes with statin use in patients with high-risk localized prostate cancer treated with radiotherapy.
    Int J Radiat Oncol Biol Phys, 79(3): 713-8. [Abstract] [Full-text]
  8. A Phase I trial of samarium-153-lexidronam complex for treatment of clinically nonmetastatic high-risk prostate cancer: first report of a completed study.
    Int J Radiat Oncol Biol Phys, 79(3): 732-7. [Abstract] [Full-text]
  9. Characterizing interfraction variations and their dosimetric effects in prostate cancer radiotherapy.
    Int J Radiat Oncol Biol Phys, 79(3): 909-14. [Abstract] [Full-text]
  10. Volumetric arc therapy and intensity-modulated radiotherapy for primary prostate radiotherapy with simultaneous integrated boost to intraprostatic lesion with 6 and 18 MV: a planning comparison study.
    Int J Radiat Oncol Biol Phys, 79(3): 920-6. [Abstract] [Full-text]
  11. Vector analysis of prostate patient setup with image-guided radiation therapy via kV cone beam computed tomography.
    Int J Radiat Oncol Biol Phys, 79(3): 915-9. [Abstract] [Full-text]
  12. Overall survival benefit from postoperative radiation therapy for organ-confined, margin-positive prostate cancer.
    Int J Radiat Oncol Biol Phys, 79(3): 719-23. [Abstract] [Full-text]
  13. Predictors of androgen deprivation therapy efficacy combined with prostatic irradiation: the central role of tumor stage and radiation dose.
    Int J Radiat Oncol Biol Phys, 79(3): 724-31. [Abstract] [Full-text]
  14. Secondary malignancies from prostate cancer radiation treatment: a risk analysis of the influence of target margins and fractionation patterns.
    Int J Radiat Oncol Biol Phys, 79(3): 738-46. [Abstract] [Full-text]
  15. Improved biochemical outcomes with statin use in patients with high-risk localized prostate cancer treated with radiotherapy.
    Int J Radiat Oncol Biol Phys, 79(3): 713-8. [Abstract] [Full-text]
  16. A Phase I trial of samarium-153-lexidronam complex for treatment of clinically nonmetastatic high-risk prostate cancer: first report of a completed study.
    Int J Radiat Oncol Biol Phys, 79(3): 732-7. [Abstract] [Full-text]
  17. Characterizing interfraction variations and their dosimetric effects in prostate cancer radiotherapy.
    Int J Radiat Oncol Biol Phys, 79(3): 909-14. [Abstract] [Full-text]
  18. Volumetric arc therapy and intensity-modulated radiotherapy for primary prostate radiotherapy with simultaneous integrated boost to intraprostatic lesion with 6 and 18 MV: a planning comparison study.
    Int J Radiat Oncol Biol Phys, 79(3): 920-6. [Abstract] [Full-text]
  19. Vector analysis of prostate patient setup with image-guided radiation therapy via kV cone beam computed tomography.
    Int J Radiat Oncol Biol Phys, 79(3): 915-9. [Abstract] [Full-text]
  20. Overall survival benefit from postoperative radiation therapy for organ-confined, margin-positive prostate cancer.
    Int J Radiat Oncol Biol Phys, 79(3): 719-23. [Abstract] [Full-text]
  21. Predictors of androgen deprivation therapy efficacy combined with prostatic irradiation: the central role of tumor stage and radiation dose.
    Int J Radiat Oncol Biol Phys, 79(3): 724-31. [Abstract] [Full-text]
  22. Secondary malignancies from prostate cancer radiation treatment: a risk analysis of the influence of target margins and fractionation patterns.
    Int J Radiat Oncol Biol Phys, 79(3): 738-46. [Abstract] [Full-text]
  23. Improved biochemical outcomes with statin use in patients with high-risk localized prostate cancer treated with radiotherapy.
    Int J Radiat Oncol Biol Phys, 79(3): 713-8. [Abstract] [Full-text]
  24. A Phase I trial of samarium-153-lexidronam complex for treatment of clinically nonmetastatic high-risk prostate cancer: first report of a completed study.
    Int J Radiat Oncol Biol Phys, 79(3): 732-7. [Abstract] [Full-text]
  25. Amplification and overexpression of vinculin are associated with increased tumour cell proliferation and progression in advanced prostate cancer.
    J Pathol, 223(4): 543-52. [Abstract] [Full-text]
  26. Gemcitabine and docetaxel in metastatic, castrate-resistant prostate cancer: results from a phase 2 trial.
    Cancer, 117(4): 752-7. [Abstract] [Full-text]
  27. Amplification and overexpression of vinculin are associated with increased tumour cell proliferation and progression in advanced prostate cancer.
    J Pathol, 223(4): 543-52. [Abstract] [Full-text]
  28. The genomic complexity of primary human prostate cancer.
    Nature, 470(7333): 214-20. [Abstract] [Full-text]
  29. SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression.
    Nature, 470(7333): 269-73. [Abstract] [Full-text]
  30. AMACR polymorphisms, dietary intake of red meat and dairy and prostate cancer risk.
    Prostate, 71(5): 498-506. [Abstract] [Full-text]
  31. Androgen hypersensitivity in prostate cancer: molecular perspectives on androgen deprivation therapy strategies.
    Prostate, 71(5): 550-7. [Abstract] [Full-text]
  32. miR-125b promotes growth of prostate cancer xenograft tumor through targeting pro-apoptotic genes.
    Prostate, 71(5): 538-49. [Abstract] [Full-text]
  33. Urinary estrogen metabolites and prostate cancer risk: a pilot study.
    Prostate, 71(5): 507-16. [Abstract] [Full-text]
  34. TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients.
    Prostate, 71(5): 489-97. [Abstract] [Full-text]
  35. A phase I study of personalized peptide vaccination using 14 kinds of vaccine in combination with low-dose estramustine in HLA-A24-positive patients with castration-resistant prostate cancer.
    Prostate, 71(5): 470-9. [Abstract] [Full-text]
  36. Human prostate cancer xenografts in lit/lit mice exhibit reduced growth and androgen-independent progression.
    Prostate, 71(5): 525-37. [Abstract] [Full-text]
  37. Drug safety is a barrier to the discovery and development of new androgen receptor antagonists.
    Prostate, 71(5): 480-8. [Abstract] [Full-text]
  38. Androgen receptors are differentially expressed in Gleason patterns of prostate cancer and down-regulated in matched lymph node metastases.
    Prostate, 71(5): 453-60. [Abstract] [Full-text]
  39. A new method to provide a fresh frozen prostate slice suitable for gene expression study and MR spectroscopy.
    Prostate, 71(5): 461-9. [Abstract] [Full-text]
  40. AMACR polymorphisms, dietary intake of red meat and dairy and prostate cancer risk.
    Prostate, 71(5): 498-506. [Abstract] [Full-text]
  41. Androgen hypersensitivity in prostate cancer: molecular perspectives on androgen deprivation therapy strategies.
    Prostate, 71(5): 550-7. [Abstract] [Full-text]
  42. miR-125b promotes growth of prostate cancer xenograft tumor through targeting pro-apoptotic genes.
    Prostate, 71(5): 538-49. [Abstract] [Full-text]
  43. Urinary estrogen metabolites and prostate cancer risk: a pilot study.
    Prostate, 71(5): 507-16. [Abstract] [Full-text]
  44. TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients.
    Prostate, 71(5): 489-97. [Abstract] [Full-text]
  45. A phase I study of personalized peptide vaccination using 14 kinds of vaccine in combination with low-dose estramustine in HLA-A24-positive patients with castration-resistant prostate cancer.
    Prostate, 71(5): 470-9. [Abstract] [Full-text]
  46. Human prostate cancer xenografts in lit/lit mice exhibit reduced growth and androgen-independent progression.
    Prostate, 71(5): 525-37. [Abstract] [Full-text]
  47. Drug safety is a barrier to the discovery and development of new androgen receptor antagonists.
    Prostate, 71(5): 480-8. [Abstract] [Full-text]
  48. Androgen receptors are differentially expressed in Gleason patterns of prostate cancer and down-regulated in matched lymph node metastases.
    Prostate, 71(5): 453-60. [Abstract] [Full-text]
  49. A new method to provide a fresh frozen prostate slice suitable for gene expression study and MR spectroscopy.
    Prostate, 71(5): 461-9. [Abstract] [Full-text]
  50. AMACR polymorphisms, dietary intake of red meat and dairy and prostate cancer risk.
    Prostate, 71(5): 498-506. [Abstract] [Full-text]
  51. Androgen hypersensitivity in prostate cancer: molecular perspectives on androgen deprivation therapy strategies.
    Prostate, 71(5): 550-7. [Abstract] [Full-text]
  52. miR-125b promotes growth of prostate cancer xenograft tumor through targeting pro-apoptotic genes.
    Prostate, 71(5): 538-49. [Abstract] [Full-text]
  53. Urinary estrogen metabolites and prostate cancer risk: a pilot study.
    Prostate, 71(5): 507-16. [Abstract] [Full-text]
  54. TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients.
    Prostate, 71(5): 489-97. [Abstract] [Full-text]
  55. A phase I study of personalized peptide vaccination using 14 kinds of vaccine in combination with low-dose estramustine in HLA-A24-positive patients with castration-resistant prostate cancer.
    Prostate, 71(5): 470-9. [Abstract] [Full-text]
  56. Human prostate cancer xenografts in lit/lit mice exhibit reduced growth and androgen-independent progression.
    Prostate, 71(5): 525-37. [Abstract] [Full-text]
  57. Drug safety is a barrier to the discovery and development of new androgen receptor antagonists.
    Prostate, 71(5): 480-8. [Abstract] [Full-text]
  58. Androgen receptors are differentially expressed in Gleason patterns of prostate cancer and down-regulated in matched lymph node metastases.
    Prostate, 71(5): 453-60. [Abstract] [Full-text]
  59. A new method to provide a fresh frozen prostate slice suitable for gene expression study and MR spectroscopy.
    Prostate, 71(5): 461-9. [Abstract] [Full-text]
  60. Primary carcinoid tumors of the urinary bladder and prostatic urethra: a clinicopathologic study of 6 cases.
    Am J Surg Pathol, 35(3): 442-6. [Abstract] [Full-text]
  61. ERG transcription factor as an immunohistochemical marker for vascular endothelial tumors and prostatic carcinoma.
    Am J Surg Pathol, 35(3): 432-41. [Abstract] [Full-text]
  62. Primary carcinoid tumors of the urinary bladder and prostatic urethra: a clinicopathologic study of 6 cases.
    Am J Surg Pathol, 35(3): 442-6. [Abstract] [Full-text]
  63. ERG transcription factor as an immunohistochemical marker for vascular endothelial tumors and prostatic carcinoma.
    Am J Surg Pathol, 35(3): 432-41. [Abstract] [Full-text]
  64. MicroRNA-100 expression is independently related to biochemical recurrence of prostate cancer.
    J Urol, 185(3): 1118-22. [Abstract] [Full-text]
  65. Effects of family history and genetic polymorphism on the cost-effectiveness of chemoprevention with finasteride for prostate cancer.
    J Urol, 185(3): 841-7. [Abstract] [Full-text]
  66. Cost-effectiveness of prostate specific antigen screening in the United States: extrapolating from the European study of screening for prostate cancer.
    J Urol, 185(3): 828-32. [Abstract] [Full-text]
  67. Efficacy of a second line luteinizing hormone-releasing hormone agonist after advanced prostate cancer biochemical recurrence.
    J Urol, 185(3): 848-54. [Abstract] [Full-text]
  68. Novel therapeutic strategies for castration resistant prostate cancer: inhibition of persistent androgen production and androgen receptor mediated signaling.
    J Urol, 185(3): 787-94. [Abstract] [Full-text]
  69. Predicting 15-year prostate cancer specific mortality after radical prostatectomy.
    J Urol, 185(3): 869-75. [Abstract] [Full-text]
  70. D'Amico risk stratification correlates with degree of suspicion of prostate cancer on multiparametric magnetic resonance imaging.
    J Urol, 185(3): 815-20. [Abstract] [Full-text]
  71. Salvage radical prostatectomy following primary high intensity focused ultrasound for treatment of prostate cancer.
    J Urol, 185(3): 862-8. [Abstract] [Full-text]
  72. Comorbidity, treatment and mortality: a population based cohort study of prostate cancer in PCBaSe Sweden.
    J Urol, 185(3): 833-9. [Abstract] [Full-text]
  73. Evaluation of prostate specific antigen acceleration for prostate cancer diagnosis.
    J Urol, 185(3): 821-6. [Abstract] [Full-text]
  74. UCH-L1 promotes cancer metastasis in prostate cancer cells through EMT induction.
    Cancer Lett, 302(2): 128-35. [Abstract] [Full-text]
  75. Dietary zinc and prostate cancer survival in a Swedish cohort.
    Am J Clin Nutr, 93(3): 586-93. [Abstract] [Full-text]
  76. Mitochondrial p32/C1QBP is highly expressed in prostate cancer and is associated with shorter prostate-specific antigen relapse time after radical prostatectomy.
    Cancer Sci, 102(3): 639-47. [Abstract] [Full-text]
  77. Inhibitory effects of the HDAC inhibitor valproic acid on prostate cancer growth are enhanced by simultaneous application of the mTOR inhibitor RAD001.
    Life Sci, 88(9): 418-24. [Abstract] [Full-text]
  78. Adoptive cell therapy of prostate cancer using female mice-derived T cells that react with prostate antigens.
    Cancer Immunol Immunother, 60(3): 349-60. [Abstract] [Full-text]
  79. UCH-L1 promotes cancer metastasis in prostate cancer cells through EMT induction.
    Cancer Lett, 302(2): 128-35. [Abstract] [Full-text]
  80. Raloxifene induces cell death and inhibits proliferation through multiple signaling pathways in prostate cancer cells expressing different levels of estrogen receptor α and β.
    J Cell Physiol, 226(5): 1334-9. [Abstract] [Full-text]
  81. Leptin increases motility and integrin up-regulation in human prostate cancer cells.
    J Cell Physiol, 226(5): 1274-82. [Abstract] [Full-text]
  82. CXCL5/ENA78 increased cell migration and epithelial-to-mesenchymal transition of hormone-independent prostate cancer by early growth response-1/snail signaling pathway.
    J Cell Physiol, 226(5): 1224-31. [Abstract] [Full-text]
  83. Raloxifene induces cell death and inhibits proliferation through multiple signaling pathways in prostate cancer cells expressing different levels of estrogen receptor α and β.
    J Cell Physiol, 226(5): 1334-9. [Abstract] [Full-text]
  84. Leptin increases motility and integrin up-regulation in human prostate cancer cells.
    J Cell Physiol, 226(5): 1274-82. [Abstract] [Full-text]
  85. CXCL5/ENA78 increased cell migration and epithelial-to-mesenchymal transition of hormone-independent prostate cancer by early growth response-1/snail signaling pathway.
    J Cell Physiol, 226(5): 1224-31. [Abstract] [Full-text]
  86. Raloxifene induces cell death and inhibits proliferation through multiple signaling pathways in prostate cancer cells expressing different levels of estrogen receptor α and β.
    J Cell Physiol, 226(5): 1334-9. [Abstract] [Full-text]
  87. Leptin increases motility and integrin up-regulation in human prostate cancer cells.
    J Cell Physiol, 226(5): 1274-82. [Abstract] [Full-text]
  88. CXCL5/ENA78 increased cell migration and epithelial-to-mesenchymal transition of hormone-independent prostate cancer by early growth response-1/snail signaling pathway.
    J Cell Physiol, 226(5): 1224-31. [Abstract] [Full-text]
  89. BMI1 silencing enhances docetaxel activity and impairs antioxidant response in prostate cancer.
    Int J Cancer, 128(8): 1946-54. [Abstract] [Full-text]
  90. BMI1 silencing enhances docetaxel activity and impairs antioxidant response in prostate cancer.
    Int J Cancer, 128(8): 1946-54. [Abstract] [Full-text]
  91. In vitro and in vivo evaluation of 64Cu-labeled SarAr-bombesin analogs in gastrin-releasing peptide receptor-expressing prostate cancer.
    J Nucl Med, 52(3): 470-7. [Abstract] [Full-text]
  92. Deriving prostate alpha-beta ratio using carefully matched groups, long follow-up and the phoenix definition of biochemical failure.
    Int J Radiat Oncol Biol Phys, 79(4): 1029-36. [Abstract] [Full-text]
  93. Prostate-specific antigen halving time while on neoadjuvant androgen deprivation therapy is associated with biochemical control in men treated with radiation therapy for localized prostate cancer.
    Int J Radiat Oncol Biol Phys, 79(4): 1022-8. [Abstract] [Full-text]
  94. Treatment results of PDR brachytherapy combined with external beam radiotherapy in 106 patients with intermediate- to high-risk prostate cancer.
    Int J Radiat Oncol Biol Phys, 79(4): 1037-42. [Abstract] [Full-text]
  95. Acute and late toxicity in a randomized trial of conventional versus hypofractionated three-dimensional conformal radiotherapy for prostate cancer.
    Int J Radiat Oncol Biol Phys, 79(4): 1013-21. [Abstract] [Full-text]
  96. Dose escalation and quality of life in patients with localized prostate cancer treated with radiotherapy: long-term results of the Dutch randomized dose-escalation trial (CKTO 96-10 trial).
    Int J Radiat Oncol Biol Phys, 79(4): 1004-12. [Abstract] [Full-text]
  97. Proteasome inhibitor-I enhances tunicamycin-induced chemosensitization of prostate cancer cells through regulation of NF-κB and CHOP expression.
    Cell Signal, 23(5): 857-65. [Abstract] [Full-text]
Place a permanent text-link or advertisement here.

© 2004-2013 Prostate Cancer Research Today. All Rights Reserved.



Prostate Cancer Research Today Archive:

Volume 1 (2004)
  Issue 1 (August)
  Issue 2 (September)
  Issue 3 (October)
  Issue 4 (November)
  Issue 5 (December)

Volume 2 (2005)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 3 (2006)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 4 (2007)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 5 (2008)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 6 (2009)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 7 (2010)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 8 (2011)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 9 (2012)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 10 (2013)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)



Prostate Cancer Books

Prostate Cancer From A to Z

Prostate Cancer From A to Z